Genesis is using a proprietary generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space) to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and chemically aware language models.

In August 2023, Genesis closed an oversubscribed $200 million round of Series B financing.